3 Psychedelic Stocks Getting High Right Now | Midas Letter RAW ft ATAI, FTRP, DRUG, Wolf Street
It has been known anecdotally that psychedelics and magic mushrooms have had therapeutic effects. This set of “drugs” have been known to positively alter mindsets, enlighten consciousness. Now, they are finally getting the proper attention for actually helping mental health disorders such as depression.
The 1960’s and the War on Drugs stunted any studies from being performed on the “magic” compounds. The result: a blanket categorization placing psychedelics into the same controlled substance list as the harshest and most addicting group of drugs with the likes of heroin.
Finally, it seems the stigma and political pressures have largely disappeared. Mainly to do with the inefficiencies of current pharmaceuticals when treating the rising mental health issues today. Researchers, scientists, patients, and investors are now keen on learning the complete medical benefits of psychedelics. This shift in mentality has led to a host of psychedelic stocks getting high and even listing on major stock exchanges like the NASDAQ.
We have 3 psychedelic shroom boom stocks interviews on deck during this show that outline this developing story. We also are lucky enough to speak to the Wolf of Wolf Street to explain and question all whats happening in the global economy today.
1.Atai Life Sciences (NASDAQ:ATAI) Founder Christian Angermayer
Atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Atai has a milestone-based funding approach that allows for efficient capital allocation towards its growing portfolio of psychedelic programs and technologies. The company currently has ten separate programs running using different compounds. Its technologies include AI-enabled computational biophysics technology that provides personalized and scalable treatment to those who might not otherwise be able to access high-quality psychological care. Atai is a young and exciting public company that started trading on the NASDAQ on June 18.
Field Trip is one of the largest vertically integrated psychedelics company’s. Its primary focus is developing novel, patented, regulated medicines targeting the serotonin 5HT2A serotonin receptor involved in psychedelic experiences to treat mental disorders, including depression and anxiety. You may also the company from its mobile app “Trip”. Trip is the first digital phone app for consciousness expansion. Field Trip recently applied to list on the NASDAQ.
Bright Minds is focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain. Its growing portfolio of next-generation serotonin agonists are designed to target abnormalities in neurocircuitry that lead to dysfunctional behaviours. Bright Minds drugs extenuate the therapeutic aspects of psychedelic while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin. Bright Minds has recently applied to list on the NASDAQ.
03:51 – **Wolf of Wolfstreet.com interview**
21:53 – How to perform due diligence?
23:30 – **Atai Life Sciences interview**
35:14 – **Field Trip interview**
48:48 – **Bright Minds interview**
1:01:18 – Favourite cannabis tickers?
1:01:56 – Best asset class to hedge against inflation?
1:02:34 – S&P run up & will it change directions?
Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.
Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.
Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.